CN104558008A - Method for synthesizing paricalcitol intermediate - Google Patents
Method for synthesizing paricalcitol intermediate Download PDFInfo
- Publication number
- CN104558008A CN104558008A CN201410803747.0A CN201410803747A CN104558008A CN 104558008 A CN104558008 A CN 104558008A CN 201410803747 A CN201410803747 A CN 201410803747A CN 104558008 A CN104558008 A CN 104558008A
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- paricalcitol
- solvent
- synthetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 41
- 229960000987 paricalcitol Drugs 0.000 title claims abstract description 35
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 title claims abstract description 35
- 230000002194 synthesizing effect Effects 0.000 title abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims abstract description 74
- 150000001875 compounds Chemical class 0.000 claims abstract description 68
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims abstract description 33
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims abstract description 30
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims abstract description 19
- 239000003054 catalyst Substances 0.000 claims abstract description 18
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229910052707 ruthenium Inorganic materials 0.000 claims abstract description 17
- 239000007800 oxidant agent Substances 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000002841 Lewis acid Substances 0.000 claims abstract description 11
- 238000007239 Wittig reaction Methods 0.000 claims abstract description 11
- 150000007517 lewis acids Chemical class 0.000 claims abstract description 11
- 230000003197 catalytic effect Effects 0.000 claims abstract description 6
- 238000000746 purification Methods 0.000 claims abstract description 6
- 230000001590 oxidative effect Effects 0.000 claims abstract description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 74
- 239000002904 solvent Substances 0.000 claims description 58
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 39
- 239000003208 petroleum Substances 0.000 claims description 33
- 238000004440 column chromatography Methods 0.000 claims description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 239000005909 Kieselgur Substances 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- JNMIXMFEVJHFNY-UHFFFAOYSA-M methyl(triphenyl)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 JNMIXMFEVJHFNY-UHFFFAOYSA-M 0.000 claims description 12
- 238000005865 alkene metathesis reaction Methods 0.000 claims description 11
- 238000003786 synthesis reaction Methods 0.000 claims description 10
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 229910052804 chromium Inorganic materials 0.000 claims description 9
- 239000011651 chromium Substances 0.000 claims description 9
- 239000011630 iodine Substances 0.000 claims description 9
- 229910052740 iodine Inorganic materials 0.000 claims description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 8
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 8
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 8
- 239000012044 organic layer Substances 0.000 claims description 8
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 claims description 8
- 238000010791 quenching Methods 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 8
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- HZXJVDYQRYYYOR-UHFFFAOYSA-K scandium(iii) trifluoromethanesulfonate Chemical compound [Sc+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F HZXJVDYQRYYYOR-UHFFFAOYSA-K 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- ZRPFJAPZDXQHSM-UHFFFAOYSA-L 1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazole;dichloro-[(2-propan-2-yloxyphenyl)methylidene]ruthenium Chemical compound CC(C)OC1=CC=CC=C1C=[Ru](Cl)(Cl)=C1N(C=2C(=CC(C)=CC=2C)C)CCN1C1=C(C)C=C(C)C=C1C ZRPFJAPZDXQHSM-UHFFFAOYSA-L 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 6
- 238000006555 catalytic reaction Methods 0.000 claims description 6
- PSCMQHVBLHHWTO-UHFFFAOYSA-K indium(iii) chloride Chemical compound Cl[In](Cl)Cl PSCMQHVBLHHWTO-UHFFFAOYSA-K 0.000 claims description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 claims description 6
- -1 triethylsilyl protecting group Chemical group 0.000 claims description 6
- 230000035484 reaction time Effects 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- PNPBGYBHLCEVMK-UHFFFAOYSA-N benzylidene(dichloro)ruthenium;tricyclohexylphosphanium Chemical compound Cl[Ru](Cl)=CC1=CC=CC=C1.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1 PNPBGYBHLCEVMK-UHFFFAOYSA-N 0.000 claims description 4
- FCDPQMAOJARMTG-UHFFFAOYSA-M benzylidene-[1,3-bis(2,4,6-trimethylphenyl)imidazolidin-2-ylidene]-dichlororuthenium;tricyclohexylphosphanium Chemical compound C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1.CC1=CC(C)=CC(C)=C1N(CCN1C=2C(=CC(C)=CC=2C)C)C1=[Ru](Cl)(Cl)=CC1=CC=CC=C1 FCDPQMAOJARMTG-UHFFFAOYSA-M 0.000 claims description 4
- 150000004683 dihydrates Chemical class 0.000 claims description 4
- 239000011984 grubbs catalyst Substances 0.000 claims description 4
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 claims description 4
- 229940080262 sodium tetrachloroaurate Drugs 0.000 claims description 4
- 239000011987 hoveyda–grubbs catalyst Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 claims description 3
- GDQLDFKZZCHAHX-UHFFFAOYSA-N CC(C=CC=C1)=C1P(C1=CC=CC=C1)C1=CC=CC=C1.I Chemical compound CC(C=CC=C1)=C1P(C1=CC=CC=C1)C1=CC=CC=C1.I GDQLDFKZZCHAHX-UHFFFAOYSA-N 0.000 claims description 2
- FIYYMXYOBLWYQO-UHFFFAOYSA-N ortho-iodylbenzoic acid Chemical group OC(=O)C1=CC=CC=C1I(=O)=O FIYYMXYOBLWYQO-UHFFFAOYSA-N 0.000 claims description 2
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 claims description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 claims description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000003513 alkali Substances 0.000 abstract description 2
- 150000001336 alkenes Chemical class 0.000 abstract 2
- 238000000354 decomposition reaction Methods 0.000 abstract 2
- 230000002349 favourable effect Effects 0.000 abstract 1
- ZVVXVFDNCIMZHX-UHFFFAOYSA-N iodo-methyl-triphenyl-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(I)(C=1C=CC=CC=1)(C)C1=CC=CC=C1 ZVVXVFDNCIMZHX-UHFFFAOYSA-N 0.000 abstract 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 41
- 239000000243 solution Substances 0.000 description 39
- 230000005526 G1 to G0 transition Effects 0.000 description 25
- 239000000741 silica gel Substances 0.000 description 25
- 229910002027 silica gel Inorganic materials 0.000 description 25
- 239000003480 eluent Substances 0.000 description 24
- 239000011734 sodium Substances 0.000 description 21
- 239000000543 intermediate Substances 0.000 description 19
- 239000002585 base Substances 0.000 description 11
- 239000011968 lewis acid catalyst Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 0 C[C@@](C(CC1)C(C)(CCC2)C1C2=O)C=C[C@](C)C(C)(C)* Chemical compound C[C@@](C(CC1)C(C)(CCC2)C1C2=O)C=C[C@](C)C(C)(C)* 0.000 description 4
- 244000089409 Erythrina poeppigiana Species 0.000 description 4
- 235000009776 Rathbunia alamosensis Nutrition 0.000 description 4
- 206010053260 Secondary hyperthyroidism Diseases 0.000 description 4
- 229910004161 SiNa Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000005579 Julia olefination reaction Methods 0.000 description 3
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 3
- 229960002061 ergocalciferol Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 235000001892 vitamin D2 Nutrition 0.000 description 3
- 239000011653 vitamin D2 Substances 0.000 description 3
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 3
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- QXTIBZLKQPJVII-UHFFFAOYSA-N triethylsilicon Chemical compound CC[Si](CC)CC QXTIBZLKQPJVII-UHFFFAOYSA-N 0.000 description 2
- CJNZAXGUTKBIHP-UHFFFAOYSA-N 2-iodobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-N 0.000 description 1
- SUADNHFMAMPGFH-WYHYYIKMSA-N C[C@@H](C(CC1)[C@@](C)(CCC2)C1/C2=C/C=C(/CCC1)\C[C@H]1O)/C=C/[C@H](C)C(C)(C)O Chemical compound C[C@@H](C(CC1)[C@@](C)(CCC2)C1/C2=C/C=C(/CCC1)\C[C@H]1O)/C=C/[C@H](C)C(C)(C)O SUADNHFMAMPGFH-WYHYYIKMSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- XLXGCFTYXICXJF-UHFFFAOYSA-N ethylsilicon Chemical compound CC[Si] XLXGCFTYXICXJF-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- HMRCZKQIOFZACX-UHFFFAOYSA-N lithium;trimethylsilylazanide Chemical compound [Li+].C[Si](C)(C)[NH-] HMRCZKQIOFZACX-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 208000025061 parathyroid hyperplasia Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
技术领域technical field
本发明涉及一种化合物的合成方法,特别涉及一种关于帕立骨化醇的中间体的合成方法,其结构如下式1所示:The present invention relates to a kind of synthetic method of compound, particularly a kind of synthetic method about the intermediate of paricalcitol, and its structure is as shown in formula 1 below:
技术背景technical background
继发性甲状腺功能亢进症(SHPT)是终末期肾脏病患者严重的并发症,可以导致心血管疾病的发生,增加病死率。帕立骨化醇是一种新型维生素D类似物,具有抑制甲状旁腺素合成、防止甲状旁腺增生的作用,对骨和肠道影响小,不升高血钙和血磷水平。目前,帕立骨化醇已经成为临床使用最广泛的SHPT预防及治疗药物,它对接受透析和移植手术前的III及IV期慢性肾脏疾病患者的SHPT都显示出了很好的预防及治疗效果。Secondary hyperthyroidism (SHPT) is a serious complication in patients with end-stage renal disease, which can lead to cardiovascular disease and increase mortality. Paricalcitol is a new vitamin D analogue, which can inhibit the synthesis of parathyroid hormone and prevent hyperplasia of parathyroid glands. It has little effect on bone and intestinal tract, and does not increase blood calcium and phosphorus levels. At present, Paricalcitol has become the most widely used drug for the prevention and treatment of SHPT in clinical practice. It has shown good preventive and therapeutic effects on SHPT in patients with stage III and IV chronic kidney disease before dialysis and transplantation. .
帕立骨化醇主要是通过多步化学合成进行制备的,其中一种重要的制备方法就是采用帕立骨化醇的中间体与砜类化合物发生Julia-Lythgoe偶联,再脱除保护基制得,其合成线路是:Paricalcitol is mainly prepared by multi-step chemical synthesis, one of the important preparation methods is to use the intermediate of Paricalcitol and the sulfone compound to undergo Julia-Lythgoe coupling, and then remove the protecting group to prepare Well, its synthetic route is:
目前已报道的制备这类帕立骨化醇的中间体的方法主要有下列几种。这些方法均是以维生素D2作为起始原料,经过数步转化得到五并六元环骨架,再采用不同的策略构建侧链中最关键、也是最难制备的反式双键,最后脱除保护基,氧化,得到这类帕立骨化醇的中间体:The methods for the preparation of such paricalcitol intermediates reported so far mainly include the following. These methods all use vitamin D2 as the starting material, undergo several steps of transformation to obtain the five- and six-membered ring skeleton, and then use different strategies to construct the most critical and most difficult trans double bond in the side chain, and finally remove the protection. base, oxidation, to obtain intermediates of such paricalcitol:
方法1:在方法1中,作者通过SN2’反应引入了侧链中的反式双键(《有机化学杂志》The Journal of Organic Chemistry,1986,51,1264-1269)。这是首个对帕立骨化醇的合成中间体的制备报道。Method 1: In method 1, the author introduced a trans double bond in the side chain through the SN 2' reaction (The Journal of Organic Chemistry, 1986, 51, 1264-1269). This is the first report on the preparation of a synthetic intermediate of paricalcitol.
但是该方法步骤繁琐,需要6步反应才能完成反式双键的建立,成本较高。However, the steps of this method are cumbersome, requiring 6 steps of reaction to complete the establishment of the trans double bond, and the cost is relatively high.
方法2:方法2是对方法1的改进(《有机化学杂志》The Journal of OrganicChemistry,1997,62,6344-6352)。Method 2: Method 2 is an improvement to Method 1 (The Journal of Organic Chemistry, 1997, 62, 6344-6352).
相比于方法1,方法2的反应步骤虽然有所缩短,但是仍需3步才能得到含有反式双键的侧链,而且由于第一步亲核加成反应的立体选择性不高,导致这一方法的总收率较低。Compared with method 1, although the reaction steps of method 2 are shortened to some extent, it still takes 3 steps to obtain the side chain containing trans double bond, and because the stereoselectivity of the first step nucleophilic addition reaction is not high, resulting in The overall yield of this method is low.
方法3:方法3采用了1,3-偶极环加成、还原、Hoffman消除等6步反应构建所需的侧链(《有机化学杂志》The Journal of Organic Chemistry,1986,51,3098-3108)。Method 3: Method 3 uses 6-step reactions such as 1,3-dipolar cycloaddition, reduction, and Hoffman elimination to construct the required side chain (The Journal of Organic Chemistry, 1986, 51, 3098-3108 ).
该方法同时引入了反式双键和25位羟基,但合成路线较长,1,3-偶极环加成反应的立体选择性不好,产品不易纯化。This method simultaneously introduces a trans double bond and a 25-position hydroxyl group, but the synthetic route is relatively long, the stereoselectivity of the 1,3-dipolar cycloaddition reaction is not good, and the product is not easy to purify.
方法4:方法4采用了Julia-Lythgoe反应建立所需的反式双键(ES 2380477A)。Method 4: Method 4 uses the Julia-Lythgoe reaction to create the desired trans double bond (ES 2380477A).
该方法的操作较为简便,但Julia-Lythgoe反应的立体选择性较差,原子经济性不高。The operation of this method is relatively simple, but the stereoselectivity of the Julia-Lythgoe reaction is poor, and the atom economy is not high.
发明内容Contents of the invention
为了克服现有的制备方法存在的不足,本发明提供了一种原料方便易得、操作简单、反应步骤少、立体选择性高的合成帕立骨化醇的中间体的方法。In order to overcome the shortcomings of the existing preparation methods, the invention provides a method for synthesizing an intermediate of paricalcitol with convenient and easy-to-obtain raw materials, simple operation, few reaction steps and high stereoselectivity.
本发明实现上述目的所采用的技术方案是该方法的合成路线为:The technical solution adopted by the present invention to realize the above object is that the synthetic route of the method is:
具体包括以下反应步骤:Concretely comprise following reaction steps:
(1)化合物II的制备(1) Preparation of compound II
在-78℃~15℃温度条件下将碘化甲基三苯基磷溶于第一溶剂中与强碱按照摩尔比为1:0.8~1.2反应15~60min,加入化合物I发生维蒂希反应0.5~10h,化合物I与碘化甲基三苯基磷的摩尔比为1:1~2,提纯,得到化合物II;Dissolve methyltriphenylphosphine iodide in the first solvent and react with a strong base at a molar ratio of 1:0.8-1.2 for 15-60 minutes at a temperature of -78°C to 15°C, and add compound I to cause a Wittig reaction 0.5~10h, the molar ratio of compound I to methyltriphenylphosphine iodide is 1:1~2, and purified to obtain compound II;
(2)化合物IV的合成(2) Synthesis of compound IV
将化合物II与化合物III按照摩尔比1:1.2~3混合后溶于第二溶剂中,在60℃~150℃温度条件下经含钌催化剂的催化发生烯烃复分解反应,化合物II与含钌催化剂的摩尔比为1:0.02~0.2,反应时间为15~48小时,提纯,得到化合物IV;Compound II and compound III are mixed according to the molar ratio of 1:1.2~3 and then dissolved in the second solvent, and olefin metathesis reaction occurs under the catalysis of ruthenium-containing catalyst under the temperature condition of 60°C-150°C, and compound II and ruthenium-containing catalyst The molar ratio is 1:0.02-0.2, the reaction time is 15-48 hours, and purified to obtain compound IV;
(3)化合物V的合成(3) Synthesis of Compound V
将化合物IV溶于第三溶剂中,在-20℃~55℃温度下用路易斯酸的催化脱除三乙基硅基保护基,催化时间为3~24小时,化合物IV与路易斯酸的摩尔比为1:0.005~0.15,提纯,得到化合物V;The compound IV is dissolved in the third solvent, and the triethylsilyl protecting group is catalyzed by a Lewis acid at a temperature of -20°C to 55°C, and the catalytic time is 3 to 24 hours. The molar ratio of the compound IV to the Lewis acid 1:0.005~0.15, purified to obtain compound V;
(4)帕立骨化醇的合成中间体VI的合成(4) Synthesis of the synthetic intermediate VI of Paricalcitol
将化合物V溶于第四溶剂中,加入高价铬或高价碘氧化剂,在-10℃~50℃温度条件下对化合物V进行氧化反应2~24小时,化合物V与高价铬或高价碘氧化剂的摩尔比为1:1~3,提纯,得到帕立骨化醇的合成中间体VI;Dissolve compound V in the fourth solvent, add hypervalent chromium or hypervalent iodine oxidizing agent, and oxidize compound V at a temperature of -10°C to 50°C for 2 to 24 hours, the mole of compound V and hypervalent chromium or hypervalent iodine oxidizing agent Ratio is 1:1~3, purify, obtain the synthetic intermediate VI of Paricalcitol;
上述第一溶剂为四氢呋喃、乙醚、乙二醇二甲醚或二氧六环;The above-mentioned first solvent is tetrahydrofuran, diethyl ether, ethylene glycol dimethyl ether or dioxane;
上述第二溶剂为二氯甲烷、1,2-二氯乙烷、苯或甲苯;The above-mentioned second solvent is dichloromethane, 1,2-dichloroethane, benzene or toluene;
上述第三溶剂为甲醇、乙醇、乙腈、水或其任意比例的混合物;The above-mentioned third solvent is methanol, ethanol, acetonitrile, water or a mixture thereof in any proportion;
上述第四溶剂为二氯甲烷、1,2-二氯乙烷、N,N-二甲基甲酰胺或二甲基亚砜。The above-mentioned fourth solvent is dichloromethane, 1,2-dichloroethane, N,N-dimethylformamide or dimethyl sulfoxide.
进一步,在步骤(1)中优选,在-20℃~0℃温度、氮气保护条件下将碘化甲基三苯基磷溶于第一溶剂中与强碱按照摩尔比为1:0.9~1反应20~60min,加入化合物I发生维蒂希反应0.5~5h,化合物I与碘化甲基三苯基磷的摩尔比为1:1~1.5,向反应液中加入饱和氯化铵溶液淬灭反应,加入石油醚萃取,用硫酸镁干燥有机层,减压旋蒸出所有溶剂,残余物经柱层析纯化,得到化合物II。所用强碱可以选择正丁基锂、二异丙基氨基锂、双三甲基硅基胺基锂、双三甲基硅基胺基钠或双三甲基硅基胺基钾等。Further, in step (1), it is preferred to dissolve methyltriphenylphosphine iodide in the first solvent and the strong base at a molar ratio of 1:0.9 to 1 at a temperature of -20°C to 0°C under nitrogen protection conditions. React for 20 to 60 minutes, add compound I to cause Wittig reaction for 0.5 to 5 hours, the molar ratio of compound I to methyltriphenylphosphine iodide is 1:1 to 1.5, add saturated ammonium chloride solution to the reaction solution to quench After reaction, petroleum ether was added for extraction, the organic layer was dried with magnesium sulfate, all solvents were evaporated under reduced pressure, and the residue was purified by column chromatography to obtain compound II. The strong base used can be selected from n-butyllithium, lithium diisopropylamide, lithium bistrimethylsilylamide, sodium bistrimethylsilylamide or potassium bistrimethylsilylamide.
进一步,在步骤(2)中优选在氮气保护下将化合物II与化合物III按照摩尔比1:1.5~2混合后溶于第二溶剂中90℃~120℃温度条件下经含钌催化剂的催化发生烯烃复分解反应,化合物II与含钌催化剂的摩尔比为1:0.05~0.1,反应时间为24~36小时,经硅藻土过滤,减压旋蒸出所有溶剂,残留物经柱层析纯化,得到化合物IV。Further, in step (2), it is preferable to mix compound II and compound III according to the molar ratio of 1:1.5~2 under the protection of nitrogen, and then dissolve them in the second solvent under the condition of 90°C~120°C under the catalysis of a ruthenium-containing catalyst. Olefin metathesis reaction, the molar ratio of compound II to the ruthenium-containing catalyst is 1:0.05-0.1, the reaction time is 24-36 hours, filtered through diatomaceous earth, and all solvents are evaporated under reduced pressure, and the residue is purified by column chromatography. Compound IV is obtained.
在上述步骤(2)中的含钌催化剂可以选择第一代Grubbs催化剂、第二代Grubbs催化剂、第一代Hoveyda-Grubbs催化剂或第二代Hoveyda-Grubbs催化剂。The ruthenium-containing catalyst in the above step (2) can be selected from first-generation Grubbs catalyst, second-generation Grubbs catalyst, first-generation Hoveyda-Grubbs catalyst or second-generation Hoveyda-Grubbs catalyst.
进一步,在步骤(3)中优选,将化合物IV溶于第三溶剂中在0℃~40℃温度下用路易斯酸催化脱除三乙基硅基保护基,催化时间为5~24小时,化合物IV与路易斯酸的摩尔比为1:0.005~0.1,经碱性三氧化铝过滤,减压旋蒸出所有溶剂,残余物经柱层析纯化,得到化合物V。Further, preferably in step (3), the compound IV is dissolved in a third solvent at a temperature of 0°C to 40°C to catalyze the removal of the triethylsilyl protecting group with a Lewis acid, and the catalytic time is 5 to 24 hours, and the compound The molar ratio of IV to Lewis acid is 1:0.005-0.1, filtered through basic alumina, and all solvents are evaporated under reduced pressure, and the residue is purified by column chromatography to obtain compound V.
上述的路易斯酸为二水合四氯金酸钠、三氯化铟、三氯化铁或三氟甲磺酸钪。The above-mentioned Lewis acid is sodium tetrachloroaurate dihydrate, indium trichloride, ferric chloride or scandium trifluoromethanesulfonate.
进一步,在上述步骤(4)中优选,将化合物V溶于第四溶剂中,加入高价铬或高价碘氧化剂在0℃~35℃温度条件下氧化化合物V 3.5~15小时,化合物V与氧化剂的摩尔比为1:1~2,经硅藻土过滤,减压旋蒸出所有溶剂,残余物经柱层析纯化,得到帕立骨化醇的合成中间体VI。Further, preferably in the above step (4), compound V is dissolved in the fourth solvent, and a hypervalent chromium or hypervalent iodine oxidant is added to oxidize compound V at a temperature of 0° C. to 35° C. for 3.5 to 15 hours. The molar ratio is 1:1~2, filtered through diatomaceous earth, all the solvents are evaporated under reduced pressure, and the residue is purified by column chromatography to obtain the synthetic intermediate VI of Paricalcitol.
上述的高价铬氧化剂可以是氯铬酸吡啶鎓或重铬酸吡啶鎓,高价碘氧化剂可以选择2-碘酰基苯甲酸或(1,1,1-三乙酰氧基)-1,1-二氢-1,2-苯碘酰-3(1H)-酮。The above-mentioned hypervalent chromium oxidizing agent can be pyridinium chlorochromate or pyridinium dichromate, and the hypervalent iodine oxidizing agent can be selected from 2-iodylbenzoic acid or (1,1,1-triacetoxy)-1,1-dihydro -1,2-Phenyliodyl-3(1H)-one.
本发明合成帕立骨化醇的中间体的方法是利用碘化甲基三苯基磷与碱反应,后加入根据已知方法由廉价的天然维生素D2制备的化合物I发生维蒂希反应,得到化合物II,化合物II再与由商品化试剂方便制备的化合物III在含钌催化剂的催化下发生烯烃复分解反应,立体专一的得到侧链含有反式双键的化合物IV,将所得化合物IV在路易斯酸的催化下选择性脱除三乙基硅基保护基,得到化合物V,用氧化剂对化合物V进行氧化,得到帕立骨化醇的合成中间体VI,其是以方便易得的化合物I和化合物III作为起始原料,提供一种操作简单、反应步骤少、立体选择性高的帕立骨化醇的中间体的制备方法,其主要优点在于:The method for synthesizing the intermediate of Paricalcitol in the present invention is to utilize iodide methyltriphenylphosphine to react with an alkali, and then add compound I prepared by a known method from cheap natural vitamin D2 to undergo a Wittig reaction to obtain Compound II, Compound II and Compound III, which is conveniently prepared by commercial reagents, undergo olefin metathesis reaction under the catalysis of a ruthenium-containing catalyst, stereospecifically obtain Compound IV with a trans double bond in the side chain, and obtain Compound IV in Lewis Under the catalysis of acid, the triethylsilyl protecting group is selectively removed to obtain compound V, and the compound V is oxidized with an oxidizing agent to obtain the synthetic intermediate VI of paricalcitol, which is based on the convenient and easy-to-obtain compound I and Compound III, as a starting material, provides a method for preparing an intermediate of Paricalcitol with simple operation, few reaction steps and high stereoselectivity, and its main advantages are:
1)原料化合物I和原料化合物III结构相对简单,容易大量制备;1) The structure of raw material compound I and raw material compound III is relatively simple, and it is easy to prepare in large quantities;
2)实验操作简便,所有步骤均未使用高毒试剂,安全性高;2) The experiment is easy to operate, no highly toxic reagents are used in all steps, and the safety is high;
3)烯烃复分解反应的立体选择性好,能够构型专一的得到侧链为反式双键的产物,简化了产品的纯化过程;3) The stereoselectivity of the olefin metathesis reaction is good, and the product whose side chain is a trans double bond can be obtained with a specific configuration, which simplifies the purification process of the product;
4)反应步骤少,总收率相对较高。4) The reaction steps are few, and the overall yield is relatively high.
因此,本发明更容易实现对帕立骨化醇的中间体的大规模制备。Therefore, the present invention is easier to realize the large-scale preparation of the paricalcitol intermediate.
具体实施方式Detailed ways
下面结合实施例对本发明的技术方案作进一步说明,但本发明不仅限于下述的实施方式。The technical solutions of the present invention will be further described below in conjunction with the examples, but the present invention is not limited to the following embodiments.
本发明帕立骨化醇的中间体VI是按照以下合成线路合成:The intermediate VI of Paricalcitol of the present invention is synthesized according to the following synthetic route:
步骤(1):化合物II的制备Step (1): Preparation of Compound II
对于化合物II的合成路径是:The synthetic route for compound II is:
具体的合成反应条件可以参照下述的几种方案:Concrete synthetic reaction conditions can refer to following several schemes:
方案a:在氮气保护下将碘化甲基三苯基磷(2.020g,5mmol)溶于10mL无水四氢呋喃中,0℃下,向上述溶液中滴加入强碱正丁基锂(3.13mL,5mmol,1.6M),搅拌反应20分钟,然后将化合物I(1.625g,5mmol)溶于10mL无水四氢呋喃中,滴加到上述反应体系中,0℃下发生维蒂希反应,反应30分钟,反应结束后,向反应液中加入饱和氯化铵溶液淬灭反应,加入石油醚萃取,用硫酸镁干燥有机层后,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是石油醚,得化合物II 1.502g,收率93%。Scheme a: Dissolve methyltriphenylphosphine iodide (2.020g, 5mmol) in 10mL of anhydrous tetrahydrofuran under nitrogen protection, and add strong base n-butyllithium (3.13mL, 5mmol, 1.6M), stirred and reacted for 20 minutes, and then compound I (1.625g, 5mmol) was dissolved in 10mL of anhydrous tetrahydrofuran, and added dropwise to the above reaction system, Wittig reaction occurred at 0°C, and reacted for 30 minutes, After the reaction is over, add saturated ammonium chloride solution to the reaction solution to quench the reaction, add petroleum ether for extraction, dry the organic layer with magnesium sulfate, spin off all solvents at 10-20mmHg under reduced pressure, and purify the residue by column chromatography , the stationary phase is silica gel, and the eluent is petroleum ether to obtain 1.502 g of compound II with a yield of 93%.
上述化合物I可以通过已知合成方法(《药物化学杂志》Journal ofMedicinal Chemistry,2000,43,3581-3586),以维生素D2为原料制得;The above-mentioned compound I can be prepared by using vitamin D2 as a raw material through a known synthetic method (Journal of Medicinal Chemistry, 2000, 43, 3581-3586);
1H NMR(600MHz,CDCl3)δ=5.66(ddd,J=8.4,10.2,16.8Hz,1H),4.89(dd,J=16.8,1.2Hz,1H),4.81(dd,J=10.2,1.8Hz,1H),4.03(br s,1H),2.09–2.03(m,1H),1.95–1.92(m,1H),1.86–1.78(m,1H),1.68–1.57(m,3H),1.38–1.29(m,3H),1.27–1.21(m,2H),1.15–1.05(m,2H),1.00(d,J=6.6Hz,3H),0.95(t,J=7.8Hz,9H),0.93(s,3H),0.55(q,J=7.8Hz,6H). 1 H NMR (600MHz, CDCl 3 ) δ = 5.66 (ddd, J = 8.4, 10.2, 16.8 Hz, 1H), 4.89 (dd, J = 16.8, 1.2 Hz, 1H), 4.81 (dd, J = 10.2, 1.8 Hz,1H),4.03(br s,1H),2.09–2.03(m,1H),1.95–1.92(m,1H),1.86–1.78(m,1H),1.68–1.57(m,3H),1.38 –1.29(m,3H),1.27–1.21(m,2H),1.15–1.05(m,2H),1.00(d,J=6.6Hz,3H),0.95(t,J=7.8Hz,9H), 0.93(s,3H),0.55(q,J=7.8Hz,6H).
ESI-HRMS理论值:C20H38OSiNa[(M+Na)+]345.2590,实测值:345.2588。ESI-HRMS calc: C 20 H 38 OSiNa [(M+Na) + ] 345.2590, found: 345.2588.
方案b:在氮气保护下将碘化甲基三苯基磷(3.030g,7.5mmol)溶于15mL无水二氧六环中,-10℃下,向上述溶液中滴加入强碱双三甲基硅基胺基钠(3.38mL,6.75mmol,2M),搅拌30分钟,然后将化合物I(1.625g,5mmol)溶于10mL无水二氧六环中,滴加到上述反应体系中,-10℃下发生维蒂希反应,反应1小时,反应结束后,向反应液中加入饱和氯化铵溶液淬灭反应,加入石油醚萃取,用硫酸镁干燥有机层后,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是石油醚,得化合物II 1.421g,收率88%。Scheme b: Dissolve methyltriphenylphosphine iodide (3.030g, 7.5mmol) in 15mL of anhydrous dioxane under the protection of nitrogen, and add a strong base bistrimethazine dropwise to the above solution at -10°C Sodium silylamide (3.38mL, 6.75mmol, 2M), stirred for 30 minutes, then compound I (1.625g, 5mmol) was dissolved in 10mL of anhydrous dioxane, and added dropwise to the above reaction system,- Wittig reaction occurs at 10°C and reacts for 1 hour. After the reaction is over, add saturated ammonium chloride solution to the reaction solution to quench the reaction, add petroleum ether for extraction, dry the organic layer with magnesium sulfate, and reduce pressure at 10-20mmHg All the solvent was evaporated by rotary evaporation, and the residue was purified by column chromatography, the stationary phase was silica gel, and the eluent was petroleum ether to obtain 1.421 g of compound II with a yield of 88%.
1H NMR(600MHz,CDCl3)δ=5.66(ddd,J=8.4,10.2,16.8Hz,1H),4.89(dd,J=16.8,1.2Hz,1H),4.81(dd,J=10.2,1.8Hz,1H),4.03(br s,1H),2.09–2.03(m,1H),1.95–1.92(m,1H),1.86–1.78(m,1H),1.68–1.57(m,3H),1.38–1.29(m,3H),1.27–1.21(m,2H),1.15–1.05(m,2H),1.00(d,J=6.6Hz,3H),0.95(t,J=7.8Hz,9H),0.93(s,3H),0.55(q,J=7.8Hz,6H). 1 H NMR (600MHz, CDCl 3 ) δ = 5.66 (ddd, J = 8.4, 10.2, 16.8 Hz, 1H), 4.89 (dd, J = 16.8, 1.2 Hz, 1H), 4.81 (dd, J = 10.2, 1.8 Hz,1H),4.03(br s,1H),2.09–2.03(m,1H),1.95–1.92(m,1H),1.86–1.78(m,1H),1.68–1.57(m,3H),1.38 –1.29(m,3H),1.27–1.21(m,2H),1.15–1.05(m,2H),1.00(d,J=6.6Hz,3H),0.95(t,J=7.8Hz,9H), 0.93(s,3H),0.55(q,J=7.8Hz,6H).
ESI-HRMS理论值:C20H38OSiNa[(M+Na)+]345.2590,实测值:345.2588。ESI-HRMS calc: C 20 H 38 OSiNa [(M+Na) + ] 345.2590, found: 345.2588.
方案c:在氮气保护下将碘化甲基三苯基磷(2.222g,5.5mmol)溶于10mL无水乙二醇二甲醚中,-20℃下,向上述溶液中滴加入强碱双三甲基硅基胺基锂(5.23mL,5.23mmol,1M),搅拌反应40分钟,然后将化合物I(1.625g,5mmol)溶于10mL无水乙二醇二甲醚中,滴加到上述反应体系中,-20℃下发生维蒂希反应,反应5小时,反应结束后,向反应液中加入饱和氯化铵溶液淬灭反应,加入石油醚萃取,用硫酸镁干燥有机层后,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是石油醚,得化合物II 1.454g,收率90%。Scheme c: Dissolve methyltriphenylphosphine iodide (2.222g, 5.5mmol) in 10mL of anhydrous ethylene glycol dimethyl ether under the protection of nitrogen, and add a strong base bis Lithium trimethylsilylamide (5.23mL, 5.23mmol, 1M), stirred for 40 minutes, and then compound I (1.625g, 5mmol) was dissolved in 10mL of anhydrous ethylene glycol dimethyl ether, and added dropwise to the above In the reaction system, a Wittig reaction occurs at -20°C for 5 hours. After the reaction, a saturated ammonium chloride solution is added to the reaction solution to quench the reaction, petroleum ether is added for extraction, and the organic layer is dried with magnesium sulfate. All the solvent was evaporated under reduced pressure at 10-20 mmHg, and the residue was purified by column chromatography with silica gel as the stationary phase and petroleum ether as the eluent to obtain 1.454 g of compound II with a yield of 90%.
1H NMR(600MHz,CDCl3)δ=5.66(ddd,J=8.4,10.2,16.8Hz,1H),4.89(dd,J=16.8,1.2Hz,1H),4.81(dd,J=10.2,1.8Hz,1H),4.03(br s,1H),2.09–2.03(m,1H),1.95–1.92(m,1H),1.86–1.78(m,1H),1.68–1.57(m,3H),1.38–1.29(m,3H),1.27–1.21(m,2H),1.15–1.05(m,2H),1.00(d,J=6.6Hz,3H),0.95(t,J=7.8Hz,9H),0.93(s,3H),0.55(q,J=7.8Hz,6H). 1 H NMR (600MHz, CDCl 3 ) δ = 5.66 (ddd, J = 8.4, 10.2, 16.8 Hz, 1H), 4.89 (dd, J = 16.8, 1.2 Hz, 1H), 4.81 (dd, J = 10.2, 1.8 Hz,1H),4.03(br s,1H),2.09–2.03(m,1H),1.95–1.92(m,1H),1.86–1.78(m,1H),1.68–1.57(m,3H),1.38 –1.29(m,3H),1.27–1.21(m,2H),1.15–1.05(m,2H),1.00(d,J=6.6Hz,3H),0.95(t,J=7.8Hz,9H), 0.93(s,3H),0.55(q,J=7.8Hz,6H).
ESI-HRMS理论值:C20H38OSiNa[(M+Na)+]345.2590,实测值:345.2588。ESI-HRMS calc: C 20 H 38 OSiNa [(M+Na) + ] 345.2590, found: 345.2588.
方案d:在氮气保护下将碘化甲基三苯基磷(3.032g,7.5mmol)加入到15mL无水乙醚中,15℃下,向上述溶液中滴加入强碱二异丙基胺基锂(4.5mL,9mmol,2M),搅拌反应15分钟,然后将化合物I(1.948g,6mmol)溶于12mL无水乙醚中,滴加到上述反应体系中,15℃下发生维蒂希反应,反应30分钟,反应结束后,向反应液中加入饱和氯化铵溶液淬灭反应,加入石油醚萃取,用硫酸镁干燥有机层后,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是石油醚,得化合物II 1.665g,收率86%。Scheme d: Add methyltriphenylphosphine iodide (3.032g, 7.5mmol) into 15mL of anhydrous ether under nitrogen protection, and add a strong base lithium diisopropylamide dropwise to the above solution at 15°C (4.5mL, 9mmol, 2M), stirred and reacted for 15 minutes, then dissolved compound I (1.948g, 6mmol) in 12mL of anhydrous ether, added dropwise to the above reaction system, Wittig reaction occurred at 15°C, and the reaction After 30 minutes, after the reaction is over, add saturated ammonium chloride solution to the reaction solution to quench the reaction, add petroleum ether for extraction, dry the organic layer with magnesium sulfate, and spin off all solvents at 10-20mmHg under reduced pressure, and the residue is passed through the column Purified by chromatography, the stationary phase was silica gel, and the eluent was petroleum ether to obtain 1.665 g of compound II with a yield of 86%.
1H NMR(600MHz,CDCl3)δ=5.66(ddd,J=8.4,10.2,16.8Hz,1H),4.89(dd,J=16.8,1.2Hz,1H),4.81(dd,J=10.2,1.8Hz,1H),4.03(br s,1H),2.09–2.03(m,1H),1.95–1.92(m,1H),1.86–1.78(m,1H),1.68–1.57(m,3H),1.38–1.29(m,3H),1.27–1.21(m,2H),1.15–1.05(m,2H),1.00(d,J=6.6Hz,3H),0.95(t,J=7.8Hz,9H),0.93(s,3H),0.55(q,J=7.8Hz,6H). 1 H NMR (600MHz, CDCl 3 ) δ = 5.66 (ddd, J = 8.4, 10.2, 16.8 Hz, 1H), 4.89 (dd, J = 16.8, 1.2 Hz, 1H), 4.81 (dd, J = 10.2, 1.8 Hz,1H),4.03(br s,1H),2.09–2.03(m,1H),1.95–1.92(m,1H),1.86–1.78(m,1H),1.68–1.57(m,3H),1.38 –1.29(m,3H),1.27–1.21(m,2H),1.15–1.05(m,2H),1.00(d,J=6.6Hz,3H),0.95(t,J=7.8Hz,9H), 0.93(s,3H),0.55(q,J=7.8Hz,6H).
ESI-HRMS理论值:C20H38OSiNa[(M+Na)+]345.2590,实测值:345.2588。ESI-HRMS calc: C 20 H 38 OSiNa [(M+Na) + ] 345.2590, found: 345.2588.
方案e:将碘化甲基三苯基磷(2.525g,6.25mmol)加入到12.5mL无水四氢呋喃中,-78℃下,向上述溶液中滴加入强碱双三甲基硅基胺基钾(5mL,5mmol,1M),搅拌反应60分钟,然后将化合物I(1.016g,3.13mmol)溶于6mL无水四氢呋喃中,滴加到上述反应体系中,-78℃下发生维蒂希反应,反应10小时,反应结束后,向反应液中加入饱和氯化铵溶液淬灭反应,加入石油醚萃取,用硫酸镁干燥有机层后,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是石油醚,得化合物II 0.868g,收率86%。Scheme e: Add methyltriphenylphosphine iodide (2.525g, 6.25mmol) into 12.5mL anhydrous tetrahydrofuran, and add a strong base potassium bistrimethylsilylamide dropwise to the above solution at -78°C (5mL, 5mmol, 1M), stirred and reacted for 60 minutes, then compound I (1.016g, 3.13mmol) was dissolved in 6mL of anhydrous tetrahydrofuran, added dropwise to the above reaction system, Wittig reaction occurred at -78°C, React for 10 hours. After the reaction is over, add saturated ammonium chloride solution to the reaction liquid to quench the reaction, add petroleum ether for extraction, dry the organic layer with magnesium sulfate, and spin off all the solvent at 10-20mmHg under reduced pressure. Purified by column chromatography with silica gel as the stationary phase and petroleum ether as the eluent to obtain 0.868 g of compound II with a yield of 86%.
上述方案a~e中所用强碱以及第一溶剂均可以相互替换,反应条件也可以在上述方案范围内调整,所得产物的收率均在86%以上。The strong bases and the first solvent used in the above schemes a to e can be replaced with each other, and the reaction conditions can also be adjusted within the range of the above schemes, and the yields of the obtained products are all above 86%.
步骤(2):化合物IV的制备Step (2): Preparation of Compound IV
化合物IV由下述合成路线合成:Compound IV is synthesized by the following synthetic route:
具体的合成反应条件可以参照下述的几种方案:Concrete synthetic reaction conditions can refer to following several schemes:
方案a:在氮气保护下将化合物II(1.454g,4.5mmol)和化合物III(2.056g,9mmol)溶于15mL无水甲苯中,向反应液中加入第二代Grubbs催化剂(382mg,0.45mmol)作为含钌催化剂,将反应液置于120℃油浴中回流反应24小时,完成烯烃复分解反应,反应结束后,经硅藻土过滤,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是石油醚,得化合物IV 1.389g,收率59%。Scheme a: Compound II (1.454g, 4.5mmol) and Compound III (2.056g, 9mmol) were dissolved in 15mL of anhydrous toluene under nitrogen protection, and the second generation Grubbs catalyst (382mg, 0.45mmol) was added to the reaction solution As a ruthenium-containing catalyst, the reaction solution was placed in an oil bath at 120°C for reflux reaction for 24 hours to complete the olefin metathesis reaction. After the reaction, it was filtered through diatomaceous earth, and all solvents were evaporated under reduced pressure at 10-20mmHg, and the residue was Purified by column chromatography, the stationary phase is silica gel, and the eluent is petroleum ether to obtain 1.389 g of compound IV with a yield of 59%.
1H NMR(600MHz,CDCl3)δ=5.28(dd,J=15.6,8.4Hz,1H),5.18(dd,J=15.6,8.4Hz,1H),4.03(br s,1H),2.03–1.97(m,2H),1.95–1.91(m,1H),1.86–1.78(m,1H),1.69–1.55(m,3H),1.38–1.19(m,6H),1.15(s,3H),1.10(s,3H),1.06(q,J=9.6Hz,1H),0.98–0.92(m,18H),0.87(s,9H),0.55(q,J=7.8Hz,6H),0.07(s,6H). 1 H NMR (600MHz, CDCl 3 ) δ=5.28(dd, J=15.6,8.4Hz,1H),5.18(dd,J=15.6,8.4Hz,1H),4.03(br s,1H),2.03–1.97 (m,2H),1.95–1.91(m,1H),1.86–1.78(m,1H),1.69–1.55(m,3H),1.38–1.19(m,6H),1.15(s,3H),1.10 (s,3H),1.06(q,J=9.6Hz,1H),0.98–0.92(m,18H),0.87(s,9H),0.55(q,J=7.8Hz,6H),0.07(s, 6H).
ESI-HRMS理论值:C31H62O2Si2Na[(M+Na)+]545.4186,实测值:545.4190。ESI-HRMS calc.: C 31 H 62 O 2 Si 2 Na [(M+Na) + ] 545.4186, found: 545.4190.
上述化合物III可以采用以下方法制备:Above-mentioned compound III can adopt following method to prepare:
①将商品化的化合物A(2.324g,10mmol)和乙酸钠(2.870g,35mmol)溶于20mL无水二氯甲烷中,向上述溶液中加入氯铬酸吡啶鎓(3.234g,15mmol),室温反应12小时,反应结束后,经硅藻土过滤,在10~20mmHg减压旋蒸出二氯甲烷,残余物经柱层析纯化,固定相是硅胶,淋洗剂是V石油 醚/V乙酸乙酯=20:1,得化合物B 2.120g,92%。① Dissolve commercially available compound A (2.324g, 10mmol) and sodium acetate (2.870g, 35mmol) in 20mL of anhydrous dichloromethane, add pyridinium chlorochromate (3.234g, 15mmol) to the above solution, and React for 12 hours. After the reaction is over, filter through diatomaceous earth, dichloromethane is evaporated under reduced pressure at 10-20mmHg, and the residue is purified by column chromatography. The stationary phase is silica gel, and the eluent is V petroleum ether /V acetic acid Ethyl ester = 20:1, to obtain 2.120g of compound B, 92%.
②在氮气保护下将碘化甲基三苯基磷(3.717g,9.2mmol)溶于19mL无水四氢呋喃中,0℃下,向上述溶液中滴加入正丁基锂(5.75mL,9.2mmol,1.6M in hexane),搅拌30分钟,然后将化合物B(2.120g,9.2mmol)溶于19mL无水四氢呋喃中,滴加到上述反应体系中,0℃下反应1小时,反应结束后,向反应液中加入饱和氯化铵溶液淬灭反应,加入石油醚萃取,用硫酸镁干燥有机层后,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是石油醚,得化合物III 1.723g,收率82%。②Dissolve methyltriphenylphosphine iodide (3.717g, 9.2mmol) in 19mL of anhydrous tetrahydrofuran under nitrogen protection, and add n-butyllithium (5.75mL, 9.2mmol, 1.6M in hexane), stirred for 30 minutes, then dissolved compound B (2.120g, 9.2mmol) in 19mL of anhydrous tetrahydrofuran, added dropwise to the above reaction system, and reacted for 1 hour at 0°C. Add saturated ammonium chloride solution to the solution to quench the reaction, add petroleum ether to extract, dry the organic layer with magnesium sulfate, and spin off all solvents at 10-20mmHg under reduced pressure, and the residue is purified by column chromatography. The stationary phase is silica gel. The eluent was petroleum ether, and 1.723 g of compound III was obtained with a yield of 82%.
1H NMR(600MHz,CDCl3)δ=5.83(ddd,J=8.4,10.8,16.8Hz,1H),4.99–4.94(m,2H),2.12–2.06(m,1H),1.17(s,3H),1.14(s,3H),1.00(d,J=7.2Hz,3H),0.87(s,9H),0.07(s,3H),0.07(s,3H). 1 H NMR (600MHz, CDCl 3 ) δ=5.83(ddd,J=8.4,10.8,16.8Hz,1H),4.99–4.94(m,2H),2.12–2.06(m,1H),1.17(s,3H ),1.14(s,3H),1.00(d,J=7.2Hz,3H),0.87(s,9H),0.07(s,3H),0.07(s,3H).
方案b:在氮气保护下将化合物II(1.454g,4.5mmol)和化合物III(1.542g,6.75mmol)溶于15mL无水苯中,向反应液中加入第二代Hoveyda-Grubbs催化剂(141mg,0.225mmol)作为含钌催化剂,将反应液置于100℃油浴中回流反应24小时,完成烯烃复分解反应,反应结束后,经硅藻土过滤,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是石油醚,得化合物IV 1.176g,收率50%。Scheme b: under nitrogen protection, compound II (1.454g, 4.5mmol) and compound III (1.542g, 6.75mmol) were dissolved in 15mL of anhydrous benzene, and the second-generation Hoveyda-Grubbs catalyst (141mg, 0.225mmol) as a ruthenium-containing catalyst, the reaction solution was placed in an oil bath at 100°C for reflux reaction for 24 hours, and the olefin metathesis reaction was completed. After the reaction was completed, it was filtered through diatomaceous earth, and all solvents were rotary evaporated at 10-20mmHg under reduced pressure. The residue was purified by column chromatography with silica gel as the stationary phase and petroleum ether as the eluent to obtain 1.176 g of compound IV with a yield of 50%.
1H NMR(600MHz,CDCl3)δ=5.28(dd,J=15.6,8.4Hz,1H),5.18(dd,J=15.6,8.4Hz,1H),4.03(br s,1H),2.03–1.97(m,2H),1.95–1.91(m,1H),1.86–1.78(m,1H),1.69–1.55(m,3H),1.38–1.19(m,6H),1.15(s,3H),1.10(s,3H),1.06(q,J=9.6Hz,1H),0.98–0.92(m,18H),0.87(s,9H),0.55(q,J=7.8Hz,6H),0.07(s,6H). 1 H NMR (600MHz, CDCl 3 ) δ=5.28(dd, J=15.6,8.4Hz,1H),5.18(dd,J=15.6,8.4Hz,1H),4.03(br s,1H),2.03–1.97 (m,2H),1.95–1.91(m,1H),1.86–1.78(m,1H),1.69–1.55(m,3H),1.38–1.19(m,6H),1.15(s,3H),1.10 (s,3H),1.06(q,J=9.6Hz,1H),0.98–0.92(m,18H),0.87(s,9H),0.55(q,J=7.8Hz,6H),0.07(s, 6H).
ESI-HRMS理论值:C31H62O2Si2Na[(M+Na)+]545.4186,实测值:545.4190。ESI-HRMS calc.: C 31 H 62 O 2 Si 2 Na [(M+Na) + ] 545.4186, found: 545.4190.
上述化合物III按照方案a中的方法制得。The above compound III was prepared according to the method in scheme a.
方案c:在氮气保护下将化合物II(1.454g,4.5mmol)和化合物III(1.851g,8.1mmol)溶于15mL无水1,2-二氯乙烷中,向反应液中加入第一代Hoveyda-Grubbs催化剂(203mg,0.338mmol)作为含钌催化剂,将反应液置于100℃油浴中回流反应36小时,完成烯烃复分解反应,反应结束后,经硅藻土过滤,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是石油醚,得化合物IV 1.130g,收率48%。Scheme c: Dissolve compound II (1.454g, 4.5mmol) and compound III (1.851g, 8.1mmol) in 15mL of anhydrous 1,2-dichloroethane under nitrogen protection, and add the first generation Hoveyda-Grubbs catalyst (203mg, 0.338mmol) is used as a ruthenium-containing catalyst, and the reaction solution is placed in an oil bath at 100°C for reflux reaction for 36 hours to complete the olefin metathesis reaction. All the solvent was distilled off by rotary distillation, and the residue was purified by column chromatography, the stationary phase was silica gel, and the eluent was petroleum ether to obtain 1.130 g of compound IV, with a yield of 48%.
1H NMR(600MHz,CDCl3)δ=5.28(dd,J=15.6,8.4Hz,1H),5.18(dd,J=15.6,8.4Hz,1H),4.03(br s,1H),2.03–1.97(m,2H),1.95–1.91(m,1H),1.86–1.78(m,1H),1.69–1.55(m,3H),1.38–1.19(m,6H),1.15(s,3H),1.10(s,3H),1.06(q,J=9.6Hz,1H),0.98–0.92(m,18H),0.87(s,9H),0.55(q,J=7.8Hz,6H),0.07(s,6H). 1 H NMR (600MHz, CDCl 3 ) δ=5.28(dd, J=15.6,8.4Hz,1H),5.18(dd,J=15.6,8.4Hz,1H),4.03(br s,1H),2.03–1.97 (m,2H),1.95–1.91(m,1H),1.86–1.78(m,1H),1.69–1.55(m,3H),1.38–1.19(m,6H),1.15(s,3H),1.10 (s,3H),1.06(q,J=9.6Hz,1H),0.98–0.92(m,18H),0.87(s,9H),0.55(q,J=7.8Hz,6H),0.07(s, 6H).
ESI-HRMS理论值:C31H62O2Si2Na[(M+Na)+]545.4186,实测值:545.4190。ESI-HRMS calc.: C 31 H 62 O 2 Si 2 Na [(M+Na) + ] 545.4186, found: 545.4190.
上述化合物III按照方案a中的方法制得。The above compound III was prepared according to the method in scheme a.
方案d:在氮气保护下将化合物II(1.454g,4.5mmol)和化合物III(1.233g,5.4mmol)溶于15mL二氯甲烷中,向反应液中加入第二代Grubbs催化剂(77mg,0.09mmol)作为含钌催化剂,将反应液加热置于60℃油浴中回流反应48小时,完成烯烃复分解反应,反应结束后,经硅藻土过滤,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是石油醚,得化合物IV 0.964g,收率41%。Scheme d: Compound II (1.454g, 4.5mmol) and Compound III (1.233g, 5.4mmol) were dissolved in 15mL of dichloromethane under nitrogen protection, and the second generation Grubbs catalyst (77mg, 0.09mmol) was added to the reaction solution ) as a ruthenium-containing catalyst, the reaction solution was heated and placed in a 60°C oil bath for reflux reaction for 48 hours to complete the olefin metathesis reaction. After the reaction was completed, it was filtered through diatomaceous earth, and all solvents were rotary evaporated at 10 to 20mmHg under reduced pressure. The compound was purified by column chromatography, the stationary phase was silica gel, and the eluent was petroleum ether to obtain 0.964 g of compound IV with a yield of 41%.
1H NMR(600MHz,CDCl3)δ=5.28(dd,J=15.6,8.4Hz,1H),5.18(dd,J=15.6,8.4Hz,1H),4.03(br s,1H),2.03–1.97(m,2H),1.95–1.91(m,1H),1.86–1.78(m,1H),1.69–1.55(m,3H),1.38–1.19(m,6H),1.15(s,3H),1.10(s,3H),1.06(q,J=9.6Hz,1H),0.98–0.92(m,18H),0.87(s,9H),0.55(q,J=7.8Hz,6H),0.07(s,6H). 1 H NMR (600MHz, CDCl 3 ) δ=5.28(dd, J=15.6,8.4Hz,1H),5.18(dd,J=15.6,8.4Hz,1H),4.03(br s,1H),2.03–1.97 (m,2H),1.95–1.91(m,1H),1.86–1.78(m,1H),1.69–1.55(m,3H),1.38–1.19(m,6H),1.15(s,3H),1.10 (s,3H),1.06(q,J=9.6Hz,1H),0.98–0.92(m,18H),0.87(s,9H),0.55(q,J=7.8Hz,6H),0.07(s, 6H).
ESI-HRMS理论值:C31H62O2Si2Na[(M+Na)+]545.4186,实测值:545.4190。ESI-HRMS calc.: C 31 H 62 O 2 Si 2 Na [(M+Na) + ] 545.4186, found: 545.4190.
上述化合物III按照方案a中的方法制得。The above compound III was prepared according to the method in scheme a.
方案e:在氮气保护下将化合物II(1.454g,4.5mmol)和化合物III(3.083g,13.5mmol)溶于15mL甲苯中,向反应液中加入第一代Grubbs催化剂(740mg,0.9mmol)作为含钌催化剂,将反应液置于150℃油浴中回流反应15小时,完成烯烃复分解反应,反应结束后,经硅藻土过滤,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是石油醚,得化合物IV 1.035g,收率44%。Scheme e: Compound II (1.454g, 4.5mmol) and Compound III (3.083g, 13.5mmol) were dissolved in 15mL of toluene under nitrogen protection, and the first generation Grubbs catalyst (740mg, 0.9mmol) was added to the reaction solution as Containing ruthenium catalyst, put the reaction solution in an oil bath at 150°C for reflux reaction for 15 hours to complete the olefin metathesis reaction. After the reaction, filter through diatomaceous earth, and rotate all the solvents under reduced pressure at 10-20mmHg, and the residue is passed through the column Purified by chromatography, the stationary phase was silica gel, and the eluent was petroleum ether to obtain 1.035 g of compound IV with a yield of 44%.
上述化合物III按照方案a中的方法制得。The above compound III was prepared according to the method in scheme a.
步骤(2)合成化合物IV的方案a~e中的催化剂可以相互替换,而且反应条件也可以在上述方案的范围内适当调整,所得化合物IV的收率均在41%以上。The catalysts in the schemes a to e of step (2) synthesizing compound IV can be replaced with each other, and the reaction conditions can also be adjusted appropriately within the scope of the above-mentioned schemes, and the yields of the obtained compound IV are all above 41%.
步骤(3):化合物V的制备Step (3): Preparation of compound V
化合物V的合成路线是:The synthetic route of compound V is:
具体可以参照下述的几种具体的实施方案进行:Concretely can carry out with reference to following several concrete implementation schemes:
方案a:将化合物IV(785mg,1.5mmol)溶于3mL甲醇中,向上述溶液中加入二水合四氯金酸钠(3mg,0.0075mmol)作为路易斯酸催化剂,25℃反应24小时,脱除三乙基硅基保护剂,反应结束后,经碱性三氧化铝过滤,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是V石油醚/V乙酸乙酯=5:1,得化合物V 582mg,收率95%。Scheme a: Compound IV (785mg, 1.5mmol) was dissolved in 3mL of methanol, and sodium tetrachloroaurate dihydrate (3mg, 0.0075mmol) was added to the above solution as a Lewis acid catalyst, and reacted at 25°C for 24 hours to remove three Ethyl silicon-based protective agent, after the reaction, filter through basic aluminum oxide, and rotate all the solvents under reduced pressure at 10-20mmHg, the residue is purified by column chromatography, the stationary phase is silica gel, and the eluent is V petroleum Ether /V ethyl acetate = 5:1 to obtain 582 mg of compound V with a yield of 95%.
1H NMR(600MHz,CDCl3)δ=5.30(dd,J=15.0,8.4Hz,1H),5.18(dd,J=15.6,8.4Hz,1H),4.07(br s,1H),2.04–1.95(m,3H),1.86–1.78(m,2H),1.72–1.64(m,1H),1.57–1.40(m,5H),1.37–1.32(m,1H),1.29–1.30(m,2H),1.18–1.13(m,4H,including 1.15(s,3H)),1.10(s,3H),0.98(d,J=6.0Hz,3H),0.96(d,J=7.2Hz,3H),0.95(s,3H),0.87(s,9H),0.07(s,6H). 1 H NMR (600MHz, CDCl 3 ) δ=5.30(dd, J=15.0,8.4Hz,1H),5.18(dd,J=15.6,8.4Hz,1H),4.07(br s,1H),2.04–1.95 (m,3H),1.86–1.78(m,2H),1.72–1.64(m,1H),1.57–1.40(m,5H),1.37–1.32(m,1H),1.29–1.30(m,2H) ,1.18–1.13(m,4H,including 1.15(s,3H)),1.10(s,3H),0.98(d,J=6.0Hz,3H),0.96(d,J=7.2Hz,3H),0.95 (s,3H),0.87(s,9H),0.07(s,6H).
ESI-HRMS理论值:C25H48O2SiNa[(M+Na)+]431.3321,实测值:431.3320。ESI-HRMS calc: C 25 H 48 O 2 SiNa [(M+Na) + ] 431.3321, found: 431.3320.
方案b:将化合物IV(785mg,1.5mmol)溶于3mL乙醇中,向上述溶液中加入三氯化铁(24mg,0.15mmol)作为路易斯酸催化剂,25℃反应5小时,脱除三乙基硅基保护剂,反应结束后,经碱性三氧化铝过滤,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是V石油 醚/V乙酸乙酯=5:1,得化合物V 563mg,收率92%。Scheme b: Dissolve compound IV (785mg, 1.5mmol) in 3mL of ethanol, add ferric trichloride (24mg, 0.15mmol) to the above solution as a Lewis acid catalyst, and react at 25°C for 5 hours to remove triethylsilicon base protecting agent, after the reaction is finished, filter through basic alumina, and rotate all the solvents under reduced pressure at 10-20mmHg, and the residue is purified by column chromatography, the stationary phase is silica gel, and the eluent is V petroleum ether /V Ethyl acetate =5:1, 563 mg of compound V was obtained, and the yield was 92%.
1H NMR(600MHz,CDCl3)δ=5.30(dd,J=15.0,8.4Hz,1H),5.18(dd,J=15.6,8.4Hz,1H),4.07(br s,1H),2.04–1.95(m,3H),1.86–1.78(m,2H),1.72–1.64(m,1H),1.57–1.40(m,5H),1.37–1.32(m,1H),1.29–1.30(m,2H),1.18–1.13(m,4H,including 1.15(s,3H)),1.10(s,3H),0.98(d,J=6.0Hz,3H),0.96(d,J=7.2Hz,3H),0.95(s,3H),0.87(s,9H),0.07(s,6H). 1 H NMR (600MHz, CDCl 3 ) δ=5.30(dd, J=15.0,8.4Hz,1H),5.18(dd,J=15.6,8.4Hz,1H),4.07(br s,1H),2.04–1.95 (m,3H),1.86–1.78(m,2H),1.72–1.64(m,1H),1.57–1.40(m,5H),1.37–1.32(m,1H),1.29–1.30(m,2H) ,1.18–1.13(m,4H,including 1.15(s,3H)),1.10(s,3H),0.98(d,J=6.0Hz,3H),0.96(d,J=7.2Hz,3H),0.95 (s,3H),0.87(s,9H),0.07(s,6H).
ESI-HRMS理论值:C25H48O2SiNa[(M+Na)+]431.3321,实测值:431.3320。ESI-HRMS calc: C 25 H 48 O 2 SiNa [(M+Na) + ] 431.3321, found: 431.3320.
方案c:将化合物IV(785mg,1.5mmol)溶于3mL乙腈与水的混合溶液(乙腈与水的体积比1:1)中,向上述溶液中加入三氯化铟(3.2mg,0.015mmol)作为路易斯酸催化剂,40℃反应8小时,脱除三乙基硅基保护剂,反应结束后,经碱性三氧化铝过滤,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是V石油醚/V乙酸乙酯=5:1,得化合物V 550mg,收率90%。Scheme c: Compound IV (785 mg, 1.5 mmol) was dissolved in 3 mL of acetonitrile and water mixed solution (volume ratio of acetonitrile and water 1:1), and indium trichloride (3.2 mg, 0.015 mmol) was added to the above solution As a Lewis acid catalyst, react at 40°C for 8 hours to remove the triethyl silicon-based protective agent. After the reaction is completed, filter through basic alumina, spin evaporate all the solvent at 10-20mmHg under reduced pressure, and pass the residue through the column layer Analysis and purification, the stationary phase is silica gel, and the eluent is V petroleum ether /V ethyl acetate = 5:1 to obtain 550 mg of compound V with a yield of 90%.
1H NMR(600MHz,CDCl3)δ=5.30(dd,J=15.0,8.4Hz,1H),5.18(dd,J=15.6,8.4Hz,1H),4.07(br s,1H),2.04–1.95(m,3H),1.86–1.78(m,2H),1.72–1.64(m,1H),1.57–1.40(m,5H),1.37–1.32(m,1H),1.29–1.30(m,2H),1.18–1.13(m,4H,including 1.15(s,3H)),1.10(s,3H),0.98(d,J=6.0Hz,3H),0.96(d,J=7.2Hz,3H),0.95(s,3H),0.87(s,9H),0.07(s,6H). 1 H NMR (600MHz, CDCl 3 ) δ=5.30(dd, J=15.0,8.4Hz,1H),5.18(dd,J=15.6,8.4Hz,1H),4.07(br s,1H),2.04–1.95 (m,3H),1.86–1.78(m,2H),1.72–1.64(m,1H),1.57–1.40(m,5H),1.37–1.32(m,1H),1.29–1.30(m,2H) ,1.18–1.13(m,4H,including 1.15(s,3H)),1.10(s,3H),0.98(d,J=6.0Hz,3H),0.96(d,J=7.2Hz,3H),0.95 (s,3H),0.87(s,9H),0.07(s,6H).
ESI-HRMS理论值:C25H48O2SiNa[(M+Na)+]431.3321,实测值:431.3320。ESI-HRMS calc: C 25 H 48 O 2 SiNa [(M+Na) + ] 431.3321, found: 431.3320.
方案d:将化合物IV(785mg,1.5mmol)溶于3mL乙腈中,向上述溶液中加入三氟甲磺酸钪(37mg,0.075mmol)作为路易斯酸催化剂,0℃反应5小时,反应结束后,经碱性三氧化铝过滤,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是V石油醚/V乙酸乙酯=5:1,得化合物V 550mg,收率90%。Scheme d: Compound IV (785 mg, 1.5 mmol) was dissolved in 3 mL of acetonitrile, and scandium trifluoromethanesulfonate (37 mg, 0.075 mmol) was added to the above solution as a Lewis acid catalyst, and reacted at 0°C for 5 hours. After the reaction, Filtrate through basic aluminum oxide, rotary evaporate all the solvent at 10-20mmHg under reduced pressure, and purify the residue by column chromatography, the stationary phase is silica gel, and the eluent is V petroleum ether /V ethyl acetate =5:1, 550 mg of compound V was obtained with a yield of 90%.
1H NMR(600MHz,CDCl3)δ=5.30(dd,J=15.0,8.4Hz,1H),5.18(dd,J=15.6,8.4Hz,1H),4.07(br s,1H),2.04–1.95(m,3H),1.86–1.78(m,2H),1.72–1.64(m,1H),1.57–1.40(m,5H),1.37–1.32(m,1H),1.29–1.30(m,2H),1.18–1.13(m,4H,including 1.15(s,3H)),1.10(s,3H),0.98(d,J=6.0Hz,3H),0.96(d,J=7.2Hz,3H),0.95(s,3H),0.87(s,9H),0.07(s,6H). 1 H NMR (600MHz, CDCl 3 ) δ=5.30(dd, J=15.0,8.4Hz,1H),5.18(dd,J=15.6,8.4Hz,1H),4.07(br s,1H),2.04–1.95 (m,3H),1.86–1.78(m,2H),1.72–1.64(m,1H),1.57–1.40(m,5H),1.37–1.32(m,1H),1.29–1.30(m,2H) ,1.18–1.13(m,4H,including 1.15(s,3H)),1.10(s,3H),0.98(d,J=6.0Hz,3H),0.96(d,J=7.2Hz,3H),0.95 (s,3H),0.87(s,9H),0.07(s,6H).
ESI-HRMS理论值:C25H48O2SiNa[(M+Na)+]431.3321,实测值:431.3320。ESI-HRMS calc: C 25 H 48 O 2 SiNa [(M+Na) + ] 431.3321, found: 431.3320.
方案e:将化合物IV(785mg,1.5mmol)溶于3mL乙醇与水的混合溶液(乙醇与水的体积比为1:5)中,向上述溶液中加入三氯化铁(36mg,0.225mmol)作为路易斯酸催化剂,-20℃反应24小时,反应结束后,经碱性三氧化铝过滤,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是V石油醚/V乙酸乙酯=5:1,得化合物V 537mg,收率88%。Scheme e: Compound IV (785 mg, 1.5 mmol) was dissolved in 3 mL of a mixed solution of ethanol and water (the volume ratio of ethanol and water was 1:5), and ferric chloride (36 mg, 0.225 mmol) was added to the above solution As a Lewis acid catalyst, it was reacted at -20°C for 24 hours. After the reaction, it was filtered through basic alumina, and all solvents were evaporated under reduced pressure at 10-20 mmHg. The residue was purified by column chromatography. The stationary phase was silica gel. The lotion was V petroleum ether /V ethyl acetate =5:1, and 537 mg of compound V was obtained with a yield of 88%.
方案f:将化合物IV(785mg,1.5mmol)溶于3mL甲醇与乙腈混合液(甲醇与乙腈体积比为1:2)中,向上述溶液中加入三氟甲磺酸钪(110mg,0.225mmol),-20℃反应10小时,反应结束后,经碱性三氧化铝过滤,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是V石油 醚/V乙酸乙酯=5:1,得化合物V 525mg,收率86%。Scheme f: Compound IV (785mg, 1.5mmol) was dissolved in 3mL of a mixture of methanol and acetonitrile (the volume ratio of methanol to acetonitrile was 1:2), and scandium trifluoromethanesulfonate (110mg, 0.225mmol) was added to the above solution , react at -20°C for 10 hours, after the reaction, filter through basic alumina, and evaporate all the solvent under reduced pressure at 10-20mmHg, the residue is purified by column chromatography, the stationary phase is silica gel, and the eluent is V Petroleum ether /V ethyl acetate =5:1 to obtain 525 mg of compound V with a yield of 86%.
方案g:将化合物IV(785mg,1.5mmol)溶于3mL水中,向上述溶液中加入二水合四氯金酸钠(30mg,0.075mmol)作为路易斯酸催化剂,55℃反应3小时,反应结束后,经碱性三氧化铝过滤,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是V石油醚/V乙酸乙酯=5:1,得化合物V 538mg,收率88%。Scheme g: Dissolve compound IV (785mg, 1.5mmol) in 3mL of water, add sodium tetrachloroaurate dihydrate (30mg, 0.075mmol) to the above solution as a Lewis acid catalyst, react at 55°C for 3 hours, after the reaction, Filtrate through basic aluminum oxide, rotary evaporate all the solvent at 10-20mmHg under reduced pressure, and purify the residue by column chromatography, the stationary phase is silica gel, and the eluent is V petroleum ether /V ethyl acetate =5:1, 538 mg of compound V was obtained with a yield of 88%.
上述制备化合物V的a~g方案中所用第三溶剂以及路易斯酸催化剂均可相互替换,而且反应条件也还可以在上述方案的范围内调整,所得化合物V的收率均在86%以上。The third solvent and the Lewis acid catalyst used in the schemes a to g of the above preparation of compound V can be replaced with each other, and the reaction conditions can also be adjusted within the scope of the above scheme, and the yield of the obtained compound V is above 86%.
步骤(4):帕立骨化醇的合成中间体VI的合成Step (4): Synthesis of the synthetic intermediate VI of Paricalcitol
按照下述合成路线合成中间体VI:Synthesize intermediate VI according to the following synthetic route:
具体的反应条件可以参照下述的几种方案实施:Concrete reaction condition can be implemented with reference to following several schemes:
方案a:将化合物V(409mg,1mmol)溶于5mL无水二氯甲烷中,向上述溶液中加入氯铬酸吡啶鎓(431mg,2mmol),25℃反应15小时,反应结束后,经硅藻土过滤,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是V石油醚/V乙酸乙酯=7:1,得化合物VI 376mg,收率92%。Scheme a: Dissolve compound V (409mg, 1mmol) in 5mL of anhydrous dichloromethane, add pyridinium chlorochromate (431mg, 2mmol) to the above solution, and react at 25°C for 15 hours. After soil filtration, all solvents were evaporated under reduced pressure at 10-20 mmHg, and the residue was purified by column chromatography, the stationary phase was silica gel, and the eluent was V petroleum ether /V ethyl acetate =7:1 to obtain 376 mg of compound VI, Yield 92%.
1H NMR(600MHz,CDCl3)δ=5.33(dd,J=15.6,8.4Hz,1H),5.19(dd,J=15.6,8.4Hz,1H),2.47–2.42(m,1H),2.30–2.18(m,2H),2.10–1.86(m,5H),1.77–1.66(m,2H),1.62–1.58(m,1H),1.52–1.44(m,2H),1.35–1.24(m,1H),1.15(s,3H),1.10(s,3H),1.04(d,J=6.6Hz,3H),0.95(d,J=6.6Hz,3H),0.86(s,9H),0.65(s,3H),0.06(s,6H). 1 H NMR (600MHz, CDCl 3 ) δ=5.33(dd, J=15.6,8.4Hz,1H),5.19(dd,J=15.6,8.4Hz,1H),2.47–2.42(m,1H),2.30– 2.18(m,2H),2.10–1.86(m,5H),1.77–1.66(m,2H),1.62–1.58(m,1H),1.52–1.44(m,2H),1.35–1.24(m,1H ),1.15(s,3H),1.10(s,3H),1.04(d,J=6.6Hz,3H),0.95(d,J=6.6Hz,3H),0.86(s,9H),0.65(s ,3H),0.06(s,6H).
ESI-HRMS理论值:C25H46O2SiNa[(M+Na)+]429.3165,实测值:429.3170。ESI- HRMS calc: C25H46O2SiNa [(M+Na) + ] 429.3165 , found: 429.3170.
方案b:将化合物V(409mg,1mmol)溶于5mL无水1,2-二氯乙烷中,向上述溶液中加入重铬酸吡啶鎓(564mg,1.5mmol),35℃反应8小时,反应结束后,经硅藻土过滤,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是V石油醚/V乙酸乙酯=7:1,得化合物VI 362mg,收率89%。Scheme b: Dissolve compound V (409mg, 1mmol) in 5mL of anhydrous 1,2-dichloroethane, add pyridinium dichromate (564mg, 1.5mmol) to the above solution, react at 35°C for 8 hours, and react After the end, filter through diatomaceous earth, rotary evaporate all the solvent at 10-20mmHg under reduced pressure, and purify the residue by column chromatography, the stationary phase is silica gel, and the eluent is V petroleum ether /V ethyl acetate =7:1 , to obtain 362 mg of compound VI, with a yield of 89%.
1H NMR(600MHz,CDCl3)δ=5.33(dd,J=15.6,8.4Hz,1H),5.19(dd,J=15.6,8.4Hz,1H),2.47–2.42(m,1H),2.30–2.18(m,2H),2.10–1.86(m,5H),1.77–1.66(m,2H),1.62–1.58(m,1H),1.52–1.44(m,2H),1.35–1.24(m,1H),1.15(s,3H),1.10(s,3H),1.04(d,J=6.6Hz,3H),0.95(d,J=6.6Hz,3H),0.86(s,9H),0.65(s,3H),0.06(s,6H). 1 H NMR (600MHz, CDCl 3 ) δ=5.33(dd, J=15.6,8.4Hz,1H),5.19(dd,J=15.6,8.4Hz,1H),2.47–2.42(m,1H),2.30– 2.18(m,2H),2.10–1.86(m,5H),1.77–1.66(m,2H),1.62–1.58(m,1H),1.52–1.44(m,2H),1.35–1.24(m,1H ),1.15(s,3H),1.10(s,3H),1.04(d,J=6.6Hz,3H),0.95(d,J=6.6Hz,3H),0.86(s,9H),0.65(s ,3H),0.06(s,6H).
ESI-HRMS理论值:C25H46O2SiNa[(M+Na)+]429.3165,实测值:429.3170。ESI- HRMS calc: C25H46O2SiNa [(M+Na) + ] 429.3165 , found: 429.3170.
方案c:将化合物V(409mg,1mmol)溶于5mL N,N-二甲基甲酰胺中,向上述溶液中加入(1,1,1-三乙酰氧基)-1,1-二氢-1,2-苯碘酰-3(1H)-酮(424mg,1mmol),0℃反应4小时,反应结束后,经硅藻土过滤,在1~5mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是V石油醚/V乙 酸乙酯=7:1,得化合物VI 368mg,收率90%。Scheme c: Dissolve compound V (409mg, 1mmol) in 5mL N,N-dimethylformamide, add (1,1,1-triacetoxy)-1,1-dihydro- 1,2-Phenyliodyl-3(1H)-one (424mg, 1mmol) was reacted at 0°C for 4 hours. After the reaction was completed, it was filtered through diatomaceous earth, and all solvents were evaporated under reduced pressure at 1~5mmHg, and the residue Purified by column chromatography, the stationary phase is silica gel, and the eluent is V petroleum ether /V ethyl acetate =7:1 to obtain 368 mg of compound VI with a yield of 90%.
1H NMR(600MHz,CDCl3)δ=5.33(dd,J=15.6,8.4Hz,1H),5.19(dd,J=15.6,8.4Hz,1H),2.47–2.42(m,1H),2.30–2.18(m,2H),2.10–1.86(m,5H),1.77–1.66(m,2H),1.62–1.58(m,1H),1.52–1.44(m,2H),1.35–1.24(m,1H),1.15(s,3H),1.10(s,3H),1.04(d,J=6.6Hz,3H),0.95(d,J=6.6Hz,3H),0.86(s,9H),0.65(s,3H),0.06(s,6H). 1 H NMR (600MHz, CDCl 3 ) δ=5.33(dd, J=15.6,8.4Hz,1H),5.19(dd,J=15.6,8.4Hz,1H),2.47–2.42(m,1H),2.30– 2.18(m,2H),2.10–1.86(m,5H),1.77–1.66(m,2H),1.62–1.58(m,1H),1.52–1.44(m,2H),1.35–1.24(m,1H ),1.15(s,3H),1.10(s,3H),1.04(d,J=6.6Hz,3H),0.95(d,J=6.6Hz,3H),0.86(s,9H),0.65(s ,3H),0.06(s,6H).
ESI-HRMS理论值:C25H46O2SiNa[(M+Na)+]429.3165,实测值:429.3170。ESI- HRMS calc: C25H46O2SiNa [(M+Na) + ] 429.3165 , found: 429.3170.
方案d:将化合物V(409mg,1mmol)溶于5mL无水二甲亚砜中,向上述溶液中加入2-碘酰基苯甲酸(420mg,1.5mmol),25℃反应3.5小时,反应结束后,经硅藻土过滤,在1~5mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是V石油醚/V乙酸乙酯=7:1,得化合物VI 360mg,收率88%。Scheme d: Dissolve compound V (409 mg, 1 mmol) in 5 mL of anhydrous dimethyl sulfoxide, add 2-iodobenzoic acid (420 mg, 1.5 mmol) to the above solution, and react at 25°C for 3.5 hours. After the reaction, Filtrate through diatomaceous earth, rotate all the solvents under reduced pressure at 1-5mmHg, and purify the residue by column chromatography, the stationary phase is silica gel, and the eluent is V petroleum ether /V ethyl acetate = 7:1 to obtain the compound VI 360mg, yield 88%.
1H NMR(600MHz,CDCl3)δ=5.33(dd,J=15.6,8.4Hz,1H),5.19(dd,J=15.6,8.4Hz,1H),2.47–2.42(m,1H),2.30–2.18(m,2H),2.10–1.86(m,5H),1.77–1.66(m,2H),1.62–1.58(m,1H),1.52–1.44(m,2H),1.35–1.24(m,1H),1.15(s,3H),1.10(s,3H),1.04(d,J=6.6Hz,3H),0.95(d,J=6.6Hz,3H),0.86(s,9H),0.65(s,3H),0.06(s,6H). 1 H NMR (600MHz, CDCl 3 ) δ=5.33(dd, J=15.6,8.4Hz,1H),5.19(dd,J=15.6,8.4Hz,1H),2.47–2.42(m,1H),2.30– 2.18(m,2H),2.10–1.86(m,5H),1.77–1.66(m,2H),1.62–1.58(m,1H),1.52–1.44(m,2H),1.35–1.24(m,1H ),1.15(s,3H),1.10(s,3H),1.04(d,J=6.6Hz,3H),0.95(d,J=6.6Hz,3H),0.86(s,9H),0.65(s ,3H),0.06(s,6H).
ESI-HRMS理论值:C25H46O2SiNa[(M+Na)+]429.3165,实测值:429.3170。ESI- HRMS calc: C25H46O2SiNa [(M+Na) + ] 429.3165 , found: 429.3170.
方案e:将化合物V(409mg,1mmol)溶于5mL二氯甲烷中,向上述溶液中加入(1,1,1-三乙酰氧基)-1,1-二氢-1,2-苯碘酰-3(1H)-酮(530mg,1.25mmol),-10℃反应24小时,反应结束后,经硅藻土过滤,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是V石油 醚/V乙酸乙酯=7:1,得化合物VI 347mg,收率85%。Scheme e: Compound V (409 mg, 1 mmol) was dissolved in 5 mL of dichloromethane, and (1,1,1-triacetoxy)-1,1-dihydro-1,2-phenyliodide was added to the above solution Acyl-3(1H)-ketone (530mg, 1.25mmol) was reacted at -10°C for 24 hours. After the reaction was completed, it was filtered through diatomaceous earth, and all solvents were evaporated under reduced pressure at 10-20mmHg, and the residue was subjected to column chromatography. For purification, the stationary phase was silica gel, and the eluent was V petroleum ether /V ethyl acetate =7:1 to obtain 347 mg of compound VI with a yield of 85%.
方案f:将化合物V(409mg,1mmol)溶于5mL 1,2-二氯乙烷中,向上述溶液中加入重铬酸吡啶鎓(1.128g,3mmol),50℃反应2小时,反应结束后,经硅藻土过滤,在10~20mmHg减压旋蒸出所有溶剂,残余物经柱层析纯化,固定相是硅胶,淋洗剂是V石油醚/V乙酸乙酯=7:1,得化合物VI 343mg,收率84%。Scheme f: Dissolve compound V (409mg, 1mmol) in 5mL 1,2-dichloroethane, add pyridinium dichromate (1.128g, 3mmol) to the above solution, react at 50°C for 2 hours, after the reaction , filtered through diatomaceous earth, all solvents were evaporated under reduced pressure at 10-20mmHg, the residue was purified by column chromatography, the stationary phase was silica gel, and the eluent was V petroleum ether /V ethyl acetate =7:1, to obtain Compound VI 343 mg, yield 84%.
合成中间体化合物VI的方案a~f中所用高价铬或高价碘可以相互替换,而且反应温度和反应时间也可以在上述方案a~f之间的范围内调整,其收率均是在84%以上。The hypervalent chromium or hypervalent iodine used in the scheme a~f of synthetic intermediate compound VI can be replaced mutually, and reaction temperature and reaction time also can be adjusted in the scope between above-mentioned scheme a~f, and its yield is all in 84% above.
综上所述,本发明的合成帕立骨化醇的中间体的方法具有原料易得、操作简单、反应步骤少、立体选择性高的优点,可以将上述各个步骤的各个方案任意组合来实现本发明帕立骨化醇的中间体的合成。In summary, the method for synthesizing the intermediate of Paricalcitol of the present invention has the advantages of easy-to-obtain raw materials, simple operation, few reaction steps, and high stereoselectivity, and can be realized by arbitrarily combining various schemes of the above-mentioned various steps. Synthesis of intermediates of paricalcitol of the present invention.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410803747.0A CN104558008B (en) | 2014-12-19 | 2014-12-19 | A kind of method for the intermediate for synthesizing paricalcitol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410803747.0A CN104558008B (en) | 2014-12-19 | 2014-12-19 | A kind of method for the intermediate for synthesizing paricalcitol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104558008A true CN104558008A (en) | 2015-04-29 |
| CN104558008B CN104558008B (en) | 2017-12-05 |
Family
ID=53075169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410803747.0A Expired - Fee Related CN104558008B (en) | 2014-12-19 | 2014-12-19 | A kind of method for the intermediate for synthesizing paricalcitol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104558008B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106117101A (en) * | 2016-06-14 | 2016-11-16 | 中国科学院化学研究所 | A kind of little Broussonetia papyrifera alkali analog and preparation method thereof and glycosidase inhibitor and application |
| WO2025108575A1 (en) * | 2023-11-21 | 2025-05-30 | Roche Diagnostics Gmbh | Methods of selective deprotection and synthesis of transhydrindane- skeleton-based compounds |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100016435A1 (en) * | 2006-05-16 | 2010-01-21 | Mcgill University | Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties |
| CN103980173A (en) * | 2014-04-26 | 2014-08-13 | 湖南华腾制药有限公司 | Preparation method of paricalcitol intermediate |
-
2014
- 2014-12-19 CN CN201410803747.0A patent/CN104558008B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100016435A1 (en) * | 2006-05-16 | 2010-01-21 | Mcgill University | Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties |
| CN103980173A (en) * | 2014-04-26 | 2014-08-13 | 湖南华腾制药有限公司 | Preparation method of paricalcitol intermediate |
Non-Patent Citations (3)
| Title |
|---|
| DANIEL T. HOG ET AL.: "The Total Synthesis of (-)-Nitidasin", 《ANGEW. CHEM. INT. ED.》 * |
| MERCEDES TORNEIRO ET AL.: "A Short, Efficient Copper-Mediated Synthesis of 1α,25-Dihydroxyvitamin D2 (1α,25-Dihydroxyergocalciferol) and C-24 Analogs1,2", 《J. ORG. CHEM.》 * |
| 朱丽娟等: "帕立骨化醇类似物的设计与合成", 《中国化学会第28届学术年会论文集》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106117101A (en) * | 2016-06-14 | 2016-11-16 | 中国科学院化学研究所 | A kind of little Broussonetia papyrifera alkali analog and preparation method thereof and glycosidase inhibitor and application |
| WO2025108575A1 (en) * | 2023-11-21 | 2025-05-30 | Roche Diagnostics Gmbh | Methods of selective deprotection and synthesis of transhydrindane- skeleton-based compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104558008B (en) | 2017-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bagutski et al. | Improved method for the conversion of pinacolboronic esters into trifluoroborate salts: facile synthesis of chiral secondary and tertiary trifluoroborates | |
| Metz et al. | Intramolecular Diels-Alder reaction of vinylsulfonates derived from hydroxyalkyl substituted 1, 3-dienes and oxidative desulfurization of the resultant sultones | |
| CN107129462A (en) | A kind of natural products (±) atisine G fully synthetic and enantiomter method for splitting | |
| CN104558008B (en) | A kind of method for the intermediate for synthesizing paricalcitol | |
| CN112321627A (en) | Axial chiral arylethynyl silane compound and preparation method thereof | |
| Quinn et al. | Convergent total synthesis of squamostolide | |
| CN113999164A (en) | Preparation method of halofuginone intermediate trans-N-benzyloxycarbonyl- (3-hydroxy-2-piperidyl) -2-acetone | |
| Cadierno et al. | Synthesis of indenyl-ruthenium (II) σ-alkynyl complexes via nucleophilic addition of (1R)-(+)-and (1S)-(−)-camphor enolates on the allenylidene group of [Ru ( C C CPh2)(η5-C9H7)(PPh3) 2][PF6]: Efficient synthesis of novel optically pure vinylidene derivatives | |
| Wang et al. | The effect of direct steric interaction between substrate substituents and ligand substituents on enantioselectivities in asymmetric addition of diethylzinc to aldehydes catalyzed by sterically congested ferrocenyl aziridino alcohols | |
| KR20190009326A (en) | Process for preparing eribulin and its intermediates | |
| CN101812046B (en) | Furan compound, synthetic method and applications | |
| Pérez-Estrada et al. | Towards taxane analogues synthesis by dienyne ring closing metathesis | |
| CN120004912B (en) | Tricyclic prostaglandin D2Preparation method of metabolite methyl ester | |
| Sezer et al. | Stereoselective synthesis of spirocyclic cyclopentapyrans by the Pauson–Khand reaction on camphor tethered enynes | |
| Reddy et al. | Stereoselective Total Synthesis of the Natural Oxylipin (6R, 7E, 9R, 10S)-6, 9, 10-Trihydroxyoctadec-7-enoic Acid1 | |
| CN114805017A (en) | Preparation method of 2-fluoro-1, 5-hexadiene compound | |
| Dittoo et al. | Synthesis of a stereoisomer of wortmannilactone C—failure and success | |
| Ho | Studies on the synthesis of tetrahydropyrans via oxa-Michael addition leading towards the total synthesis of Montanacin D | |
| CN113292630B (en) | Methods for Asymmetric Synthesis of Triptonide and Triptolide | |
| Morten et al. | New synthetic strategies for the stereocontrolled synthesis of substituted ‘skipped’diepoxides | |
| CN101139274B (en) | Method for synthesizing coenzyme Q10 with olefin metathesis reaction | |
| CN108503652B (en) | A kind of chemical total synthesis preparation method of crotonane diterpene Prostratin | |
| CN102295679A (en) | Sesterterpene compound and purpose thereof | |
| CN115536530A (en) | A kind of chemical total synthesis method of Vulgarisin type tetracyclic diterpene compound | |
| Salva Reddy et al. | Stereoselective Total Synthesis of the Natural Oxylipin (6R, 7E, 9R, 10S)‐6, 9, 10‐Trihydroxyoctadec‐7‐enoic Acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171205 Termination date: 20201219 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |